Rapid, accurate detection of carbapenemase-producing organisms (CPOs) and 25 the classification of their carbapenemases are valuable tools for reducing the mortality 26 of the CPO-associated infections, preventing the spread of CPOs, and optimizing use of 27 new β-lactamase inhibitor combinations such as ceftazidime/avibactam and 28 meropenem/vaborbactam. The current study evaluated the performance of CPO
5 86 catalog # 97062-476). This solution was pH adjusted to pH 7.0 using 10N NaOH & 12N 87 HCl. 88 Thirty μl of solution A was dispensed into transparent vessels such as PCR tubes (VWR 89 International catalog # 20170-004) or microtiter wells. One tube was used for each test 90 isolate and two additional tubes were used for testing a positive and negative control 91 isolates. Colonies of each bacterial test isolate and a positive and negative control 92 isolate were harvested with a 1 μl loop (VWR International, catalog # 12000-806) from 93 blood agar (BD Diagnostics Systems, Sparks, MD, USA). The volume of harvested 94 inoculum was sufficient to provide a slightly convex surface after filling the loop aperture 95 e.g. similar to the amount of convex curvature of these two parentheses (). Excess 96 inoculum was avoided to ensure test accuracy. The inoculum for each isolate was 97 suspended in 30 μl of Solution A by vigorously rotating the loop in the solution.
98
Inoculated tubes were then incubated at room temperature until positive or for a 99 maximum of 90 minutes. The test was interpreted in bright light against a white 100 background by comparing the color of the inoculated test to the negative control K. 101 aerogenes G1614. A positive test was interpreted as the development of yellow, orange 102 or a lighter shade of red than the red negative control (Fig 1) . Tests were performed 103 blinded. which tests were performed blinded, the classification phase of the study was proof-of-112 concept testing with carbapenemase classifications known at the time of testing.
113
Three solutions were used for classification. These were solutions A (described above), possibly also to the other β-lactamase inhibitor combinations currently in development.
198
In particular, the potential for development of resistance to avibactam (21, 22) is a 199 concern as resistance to it may impart cross-resistance to the related 
